TY - JOUR
T1 - Effetti emodinamici della somministrazione in vivo dell'Insulin-like Growth Factor-I
AU - Gaspari, A.
AU - Luzzana, F.
AU - Rademacher, J.
AU - Adams, G.
AU - Innocente, F.
AU - Passalia, L.
AU - Bellinzona, G.
AU - Noli, S.
AU - Dionigi, P.
AU - Zonta, F.
AU - Barbieri, A.
AU - Zonta, A.
AU - Maestri, M.
PY - 1998/9
Y1 - 1998/9
N2 - Background. Recent studies have demonstrated that IGF-I has several biological activities that correlate with the GH axis, by acting as a cell protecting factor and a promoting compound in different tissues and organs. Our latest findings have demonstrated a potential application of IGF-I in the treatment of postischemic renal injury, which frequently appears after a kidney transplant. The beneficial effect of the renal postoperative recovery probably correlates with the regulation of the vascular tone, in which IGF-I plays a role with other cytokines. However, this rises the question whether IGF-I has any effect on the general hemodynamic status. This study was designed to underline the intraoperative hemodynamic effect of exogenous IGF-I in an experimental setting of renal transplantation in swine. Methods. Twelve female swine underwent a left renal autotransplantation. At the reperfusion the animals were separated in two groups. Group one served as control. Group two received 400 μg of IGF-I (added to the flushing solution). The animals were kept under complete hemodynamic monitoring over the operation. Results. Among the different parameters studied (mean arterial pressure, mean pulmonary arterial pressure, pulmonary wedge pressure, central venous pressure, cardiac output oxygen extraction ratio, systemic vascular resistance, oxygen delivery and oxygen consumption), any statistically significant difference between group one and two were observed. Conclusions. While the clinical administration of IGF-I requires further studies, the in vivo administration of this peptide is apparently well tolerated, and does not cause any hemodynamic instability to the operation.
AB - Background. Recent studies have demonstrated that IGF-I has several biological activities that correlate with the GH axis, by acting as a cell protecting factor and a promoting compound in different tissues and organs. Our latest findings have demonstrated a potential application of IGF-I in the treatment of postischemic renal injury, which frequently appears after a kidney transplant. The beneficial effect of the renal postoperative recovery probably correlates with the regulation of the vascular tone, in which IGF-I plays a role with other cytokines. However, this rises the question whether IGF-I has any effect on the general hemodynamic status. This study was designed to underline the intraoperative hemodynamic effect of exogenous IGF-I in an experimental setting of renal transplantation in swine. Methods. Twelve female swine underwent a left renal autotransplantation. At the reperfusion the animals were separated in two groups. Group one served as control. Group two received 400 μg of IGF-I (added to the flushing solution). The animals were kept under complete hemodynamic monitoring over the operation. Results. Among the different parameters studied (mean arterial pressure, mean pulmonary arterial pressure, pulmonary wedge pressure, central venous pressure, cardiac output oxygen extraction ratio, systemic vascular resistance, oxygen delivery and oxygen consumption), any statistically significant difference between group one and two were observed. Conclusions. While the clinical administration of IGF-I requires further studies, the in vivo administration of this peptide is apparently well tolerated, and does not cause any hemodynamic instability to the operation.
KW - Hemodynamics
KW - Insulin-like Growth Factor-I (IGF-I)
KW - Kidney transplantation
UR - http://www.scopus.com/inward/record.url?scp=7844241907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7844241907&partnerID=8YFLogxK
M3 - Articolo
C2 - 9866934
AN - SCOPUS:7844241907
VL - 53
SP - 691
EP - 699
JO - Minerva Chirurgica
JF - Minerva Chirurgica
SN - 0026-4733
IS - 9
ER -